Levobupivacaína Altan

Levobupivacaine, the active ingredient in Levobupivacaína Altan, is a local anesthetic presented for epidural use. It provides reversible nerve blockade for surgical anesthesia, labor analgesia, and postoperative pain management in adult patients, offering a stereoselective formulation with a prolonged duration and reduced cardiotoxicity compared with racemic bupivacaine.

GNH USA supplies Levobupivacaína Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levobupivacaine is a local anesthetic used in the epidural pathway to provide analgesia and anesthesia. - Surgical procedures: provides epidural anesthesia for intra‑operative pain control. - Labor: offers analgesia during childbirth. - Post‑operative care: manages pain after surgery.

Adverse reactions may occur after epidural administration of levobupivacaine.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Bradycardia: slowed heart rate. - Nausea: mild to moderate upset stomach. - Injection site pain: discomfort at the epidural site.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Seizures: central nervous system excitation. - Respiratory depression: reduced breathing effort. - Systemic toxicity: signs of central or cardiovascular toxicity such as tinnitus, metallic taste, or loss of consciousness.

When using levobupivacaine, clinicians should observe specific safety measures. - Cardiovascular monitoring: continuously assess heart rate and blood pressure during epidural infusion. - Dose adjustment: avoid high concentrations in patients with pre‑existing cardiac disease. - Allergy assessment: screen for hypersensitivity to amide‑type local anesthetics. - Concurrent CNS depressants: use caution when combined with other agents that depress respiration. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levobupivacaine may interact with other drugs, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine): increase risk of cardiotoxicity. - Other local anesthetics: additive toxicity when administered together.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - General anesthetics (e.g., propofol): may potentiate central nervous system depression. - Opioids: may increase risk of respiratory depression.